Tacrolimus and Azathioprine Versus Cyclosporine and Mycophenolate Mofetil After Lung Transplantation: A Retrospective Cohort Study

Journal of Heart and Lung Transplantation

Volumn 28, Issue 7, 2009, Pages 697-703

  Celik, Muhammet R ^a   Lederer, David J ^a   Wilt, Jessie ^a   Eser, Dilek ^b   Bacchetta, Matthew ^a   D'Ovidio, Frank ^a   Sonett, Joshua R ^a   Arcasoy, Selim M ^a  

^a Columbia University Medical Center ^*  (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SURVIVAL RATE; TRANSBRONCHIAL BIOPSY; VIRUS INFECTION;

ADULT; AGED; AZATHIOPRINE; BIOPSY; COHORT STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 67649101313     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.04.010     Document Type: Article

References (21)

1. Trulock E.P., Christie J.D., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 26 (2007) 782-795
2. Boehler A., and Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 6 (2000) 133-139
3. Briffa N., and Morris R.E. New immunosuppressive regimens in lung transplantation. Eur Respir J 10 (1997) 2630-2637
4. Husain A.N., Siddiqui M.T., Holmes E.W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 159 (1999) 829-833
5. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
6. Glanville A.R., Aboyoun C.L., Havryk A., Plit M., Rainer S., and Malouf M.A. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 177 (2008) 1033-1040
7. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation(ISHLT). Am J Respir Crit Care Med 158 (1998) 335-339
8. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 15 (1996) 1-15
9. Hachem R.R., Yusen R.D., Chakinala M.M., et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 26 (2007) 1012-1018
10. Keenan R.J., Konishi H., Kawai A., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 60 (1995) 580-584 discussion 584-5
11. Treede H., Klepetko W., Reichenspurner H., et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 20 (2001) 511-517
12. Zuckermann A., Reichenspurner H., Birsan T., et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 125 (2003) 891-900
13. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24 (2005) 119-130
14. McCurry K.R., Iacono A.T., Dauber J.H., et al. Lung and heart-lung transplantation at the University of Pittsburgh. Clin Transpl (1997) 209-218
15. Reichenspurner H., Kur F., Treede H., et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 68 (1999) 67-71
16. Ross D.J., Waters P.F., Levine M., Kramer M., Ruzevich S., and Kass R.M. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 17 (1998) 768-774
17. Zuckermann A., Klepetko W., Birsan T., et al. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 18 (1999) 432-440
18. Palmer S.M., Baz M.A., Sanders L., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 71 (2001) 1772-1776
19. McNeil K., Glanville A.R., Wahlers T., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
20. Lama V.N., Murray S., Lonigro R.J., et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 175 (2007) 1192-1198
21. Miettinen O.S. The need for randomization in the study of intended effects. Stat Med 2 (1983) 267-271